Fig. 3: Kaplan–Meier probability estimates of OS in training cohort 1 and training cohort 2. | Leukemia

Fig. 3: Kaplan–Meier probability estimates of OS in training cohort 1 and training cohort 2.

From: Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis

Fig. 3

A Kaplan–Meier probability estimates of OS in training cohort 1 (n = 180) were presented across the clinical survival model risk categories. The cytogenetic information or survival status of 26 patients in training cohort 1 was not available. Thus, 154 patients were included in the clinical survival model. Patients were divided into three categories: low (median OS 96 months, 95% CI unavailable), intermediate (median OS 64 months, 95% CI 56–72 months) and high risk (median OS 36 months, 95% CI 18–55 months) (low versus intermediate risk, P < 0.001; low versus high risk, P < 0.001; intermediate versus high risk, P = 0.001). B Kaplan–Meier probability estimates of OS in training cohort 2 (n = 122) were presented across the clinical-molecular survival model risk categories. The cytogenetic information and survival status of 12 patients were not available for training cohort 2. Thus, 110 patients were included in the clinical-molecular survival model. Patients were divided into three categories: low (median OS not reached), intermediate (median OS 65 months, 95% CI 55–76 months) and high risk (median OS 30 months, 95% CI 23–36 months) (low versus intermediate risk, P = 0.011; low versus high risk, P < 0.001; intermediate versus high risk, P < 0.001). OS overall survival.

Back to article page